Table 1. Demographic and clinical characteristics by therapy (N=493); data from the Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) Cohort 2000-2009b.
| Characteristics | Fenofibrate (n=80) |
Gemfibrozil (n=46) |
Fish Oil (n=76) |
Atorvastatin (n=291) |
P value |
|---|---|---|---|---|---|
| Age (years) | 0.4 | ||||
| <40 | 17 (21) | 14 (31) | 18 (24) | 64 (22) | |
| 40-49 | 39 (48) | 24 (52) | 36 (47) | 127 (44) | |
| ≥50 | 24 (31) | 8 (17) | 22 (29) | 100 (34) | |
| Sex | 0.1 | ||||
| Male | 76 (95) | 45 (98) | 76 (100) | 273 (94) | |
| Female | 4 (5) | 1 (2) | 0 | 18 (6) | |
| Race | 0.1 | ||||
| White | 52 (65) | 25 (55) | 51 (67) | 177 (61) | |
| Black | 12 (15) | 13 (28) | 6 (8) | 63 (22) | |
| Hispanic | 14 (17) | 6 (13) | 15 (20) | 36 (12) | |
| Other | 2 (3) | 2 (4) | 4 (5) | 15 (5) | |
| Body mass index (kg/m2)c | 0.2 | ||||
| <18.5 | 2 (2) | 3 (7) | 6 (8) | 15 (5) | |
| 18.5-25 | 20 (25) | 13 (30) | 24 (31) | 95 (33) | |
| 25.1-30 | 37 (47) | 22 (51) | 31 (41) | 101 (35) | |
| >30.0 | 21 (26) | 5 (12) | 15 (20) | 78 (27) | |
| Diabetes | 0.05 | ||||
| Yes | 13 (16) | 1 (2) | 5 (7) | 33 (11) | |
| No | 67 (84) | 45 (98) | 71 (93) | 258 (89) | |
| Pre-index TG (mg/dl) | 467 | 440 | 366 | 295 | <0.01 |
| Post-index TG (mg/dl)a | 351 | 273 | 326 | 254 | <0.01 |
| HIV risk factor | 0.004 | ||||
| MSM | 43 (54) | 32 (70) | 48 (63) | 190 (65) | |
| IDU | 2 (3) | 3 (6) | 6 (8) | 15 (5) | |
| Heterosexual | 30 (37) | 9 (20) | 13 (17) | 80 (28) | |
| Other | 5 (6) | 2 (4) | 9 (12) | 6 (2) | |
| CD4+ cell count (cells/mm3) | 0.001 | ||||
| 0-200 | 7 (9) | 11 (24) | 15 (20) | 36 (12) | |
| 201-350 | 18 (22) | 20 (43) | 15 (20) | 67 (23) | |
| >350 | 55 (69) | 15 (33) | 46 (60) | 188 (65) | |
| HIV-1 RNA (copies/ml) | 0.1 | ||||
| 0-9,999 | 70 (87) | 43 (94) | 69 (91) | 265 (91) | |
| 10,000-99,999 | 10 (13) | 3 (6) | 3 (4) | 19 (7) | |
| ≥100,000 | 0 | 0 | 4 (5) | 7 (2) | |
| Antiretroviral therapy regimen | 0.001 | ||||
| PI-based | 34 (43) | 18 (39) | 48 (63) | 107 (37) | |
| NNRTI-based | 18 (22) | 9 (20) | 10 (13) | 62 (21) | |
| Other ART | 10 (13) | 12 (26) | 6 (8) | 47 (16) | |
| None | 18 (22) | 7 (15) | 12 (16) | 75 (26) |
a
Average time period between the pre and post TG laboratory measurements was 5 months.
ART, antiretroviral therapy; MSM, men who have sex with men; IDU, injection drug use; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.
b
Restricted to baseline TG value >150 mg/dl and <810 mg/dl.
c
There was missing data for BMI in atorvastatin group (n=2)